Shakeel Modak

Chief, Neuroblastoma Service · New York Presbyterian Hospital

Credentials: · · · ·

History

Phase I Study Humanized 3F8 MoAb (IND 112594) and NK Cells (IND BB-13399) for Neuroblastoma
Food and Drug Administration · R01
PI · $749.7K · Sloan-Kettering Inst Can Research
2016–2020
Combination Immunotherapy for Neuroblastoma: Model of Innate Tumor Immunity
National Cancer Institute · R01
PI · $1.1M · Sloan-Kettering Inst Can Research
2012–2016
Phase 1 Study of Immunotherapy with NK Cells Anti-GD2 for Neuroblastoma
Food and Drug Administration · R01
PI · $600K · Sloan-Kettering Inst Can Research
2012–2015
Combination of Targeted Radiotherapy and Anti-Angiogenesis for Resistant Neurobla
National Cancer Institute · R21
Contact PI · $841.5K · Sloan-Kettering Inst Can Research
2008–2010

Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Principal investigator · Active not recruiting · Early phase 1
Memorial Sloan Kettering Cancer Center
2017–2027
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2016–2025
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
Principal investigator · Active not recruiting
Memorial Sloan Kettering Cancer Center
2014–2026
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2010–2018